Hormones: Injections of goserelin - Zoladex given alongside chemotherapy in women with breast cancer who are menstruating completely protect ovaries. Freezing seems better alternative. Article updated August 3, 2011

May 7, 2011: Source: Journal of Clinical Oncology

When young women with breast cancer who receive chemotherapy in addition to goserelin injections - Zoladex then that no significant protection of the ovaries. According to a randomized study of 60 women with breast cancer who were younger than 48 years. This study was specifically designed to see if with the help of goserelin injections - Zoladex menstruation normally earlier going to come after chemotherapy. This was not the case. There was no apparent difference between the group of women who have had the injections and the women who did not receive injections. In both groups took an average of 6 months after chemotherapy for menstruation was normal again. Here is the abstract of the study:

Source: Journal of Clinical Oncology

 

Patients with premenopausal breast cancer modern Receiving goserelin simultaneously with neoadjuvant chemotherapy did not experience statistically significantly less amenorrhea 6 months after end of chemotherapy compared with chemotherapy alone Those Receiving.

Effect of Luteinizing Hormone-Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study

  1. Bernd Gerber ,
  2. Gunter von Minckwitz ,
  3. Heinrich Stehle ,
  4. Toralf Reimer ,
  5. Ricardo Felberbaum ,
  6. Nikolai Maass ,
  7. Dorothea Fischer ,
  8. Harald L. Sommer ,
  9. Bettina Conrad ,
  10. Olaf Ortmann ,
  11. Tanja Fehm ,
  12. Mahdi Rezai ,
  13. Keyur Mehta and
  14. Sibylle Loibl ⇓

+ Author Affiliations

  1. From the University of Rostock, Rostock, Germantown Breast Group, Neu-Isenburg, Vinzenz von Paul-Kliniken, Marie Hospital, Stuttgart, Klinikum Kempten Oberallgäu Kempten, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Klinikum der Ludwig-Maximilians-Universität, Maistrasse Women's Hospital, Munich, Kassel Elizabeth Hospital, Breast Center, Kassel, University of Regensburg, Regensburg, University Women's Hospital, Tübingen, and Luisenkrankenhaus, Dusseldorf, Germany.
  1. Ding Corresponding author: Sibylle Loibl, MD, PhD, Germantown Breast Group, GBG Forschungs GmbH, Martin-Behaim-Str. 12, 63263 Neu-Isenburg, Germany, e-mail: @ sibylle.loibl germanbreastgroup.de .

Abstract

Observational studies Purpose Suggested That luteinizing hormone-releasing hormone agonists (LHRHa) Might Prevent premature ovarian failure result from using adjuvant chemotherapy in premenopausal patient. We Aimed to test the efficacy of ovarian function preservation with the LHRHa goserelin in patients with breast cancer.

Patients and Methods In a prospective, randomized, open-label, controlled multicenter study, 60 patients younger than age 46 years with hormone-insensitive breast cancer were Allocated to receive anthracycline / cyclophosphamide (with or without taxanes)-based neoadjuvant chemotherapy with or without goserelin. The first goserelin injection was at least 2 weeks before Administered the first chemotherapy cycle, continuing at 3.6 mg subcutaneously every 4 weeks Until The End of the last cycle. The primary objective was the reappearance of normal ovarian function, defined as two within-Consecutive menstrual periods 21 to 35 days at 6 months after end of chemotherapy.

Results Fifty-three Patients (88.3%) Experienced temporary amenorrhea (93.3% v 83.3% with without goserelin). No significant difference was observed Regarding the reappearance of menstruation at 6 months after chemotherapy (70.0% v 56.7% with goserelin without, or 13.3% difference, 95% CI, -10.85 to 37.45, P = .284). All but one evaluable patient reported regular menses at 2 years after chemotherapy. Time to restoration of menstruation was 6.8 months (95% CI, 5.2 to 8.4) with goserelin and 6.1 months (95% CI, 5.3 to 6.8) without goserelin (P = .304). Chemotherapy resulted in a Decreased ovarian reserve Measured by inhibin B and anti-Müllerian hormone consistently follow up, supporting the Other Findings.

Conclusion Patients with premenopausal breast cancer modern Receiving goserelin simultaneously with neoadjuvant chemotherapy did not experience statistically significantly less amenorrhea 6 months after end of chemotherapy compared with chemotherapy alone Those Receiving.